Advertisement

Topics

FDA Approves Seattle Genetics’ Adcetris for pcALCL and CD30-Expressing MF

14:01 EST 9 Nov 2017 | Speciality Pharma Journal

BOTHELL, Wash.–(BUSINESS WIRE)–Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that the U.S. Food and Drug Administration (FDA) has approved ADCETRIS (brentuximab vedotin) for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) and CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy. Primary cutaneous ALCL and MF are the most common …

Original Article: FDA Approves Seattle Genetics’ Adcetris for pcALCL and CD30-Expressing MF

NEXT ARTICLE

More From BioPortfolio on "FDA Approves Seattle Genetics’ Adcetris for pcALCL and CD30-Expressing MF"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...